Structural basis for the binding of high affinity phosphopeptides to Stat3

Signal transducer and activator of transcription 3 (Stat3) is constitutively active in a number of cancers where it participates in aberrant transcription of prosurvival, cell cycling, and angiogenesis genes. Since Stat3 initiates its signaling activity through binding of its SH2 domain to phosphotyrosine residues on cell surface receptors, inhibitors targeting this region of the protein are potential chemotherapeutic agents. To date, no NMR or X‐ray crystallographic structures of high‐affinity phosphopeptides complexed with the Stat3 SH2 domain are available to aid in the development of peptidomimetic antagonists. Examination of the crystal structures of several STAT proteins and the complex of Stat1 with Ac‐pTyr‐Asp‐Lys‐Pro‐His‐NH2 led to a hypothesis that the specificity determinant for Stat3, glutamine at position pY+3 in pTyr‐Xxx‐Xxx‐Gln sequences, resides in a unique pocket on the protein surface at the juncture of the third strand of the central β‐sheet and a unique, STAT specific α‐helix. Docking of Ac‐pTyr‐Leu‐Pro‐Gln‐NHBn to the SH2 domain of Stat3 using molecular modeling showed that the Gln binds tightly in this pocket and participates in a network of hydrogen bonds. Novel interactions between the peptide main chain and the protein were also discovered. Phosphopeptide structure‐affinity studies using unnatural amino acids and glutamine derivatives provide evidence for the peptide‐protein interactions revealed by the model and lend support to the binding hypothesis. © 2007 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 90: 69–79, 2008.

[1]  S. Harrison,et al.  Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck , 1993, Nature.

[2]  P. Coffer,et al.  EGF receptor deletions define a region specifically mediating STAT transcription factor activation. , 1995, Biochemical and biophysical research communications.

[3]  J. Darnell,et al.  Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors , 1995, Science.

[4]  L. Cantley,et al.  Recognition and specificity in protein tyrosine kinase-mediated signalling. , 1995, Trends in biochemical sciences.

[5]  D. G. Davis,et al.  Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide. , 1995, Biochemistry.

[6]  R. Schreiber,et al.  Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. , 1995, Immunity.

[7]  Axel Wollmer,et al.  Differential Activation of Acute Phase Response Factor/Stat3 and Stat1 via the Cytoplasmic Domain of the Interleukin 6 Signal Transducer gp130 , 1996, The Journal of Biological Chemistry.

[8]  A. Breeze,et al.  Structure of a specific peptide complex of the carboxy‐terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3‐kinase. , 1996, The EMBO journal.

[9]  Jens Schneider-Mergener,et al.  Differential Activation of Acute Phase Response Factor/STAT3 and STAT1 via the Cytoplasmic Domain of the Interleukin 6 Signal Transducer gp130 , 1996, The Journal of Biological Chemistry.

[10]  D. Erdmann,et al.  Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode , 1996, Nature Structural Biology.

[11]  D Cowburn,et al.  Modular peptide recognition domains in eukaryotic signaling. , 1997, Annual review of biophysics and biomolecular structure.

[12]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.

[13]  T K Sawyer,et al.  Src homology‐2 domains: Structure, mechanisms, and drug discovery , 1998, Biopolymers.

[14]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[15]  J. Darnell,et al.  Crystal Structure of a Tyrosine Phosphorylated STAT-1 Dimer Bound to DNA , 1998, Cell.

[16]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[17]  M. Cascio,et al.  Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. , 1999, Blood.

[18]  P. Ettmayer,et al.  Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1). , 1999, Journal of medicinal chemistry.

[19]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[20]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[21]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[22]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Müller.  Peptidomimetic SH2 Domain Antagonists for Targeting Signal Transduction , 2000 .

[24]  R. Panek,et al.  Progress in the development of inhibitors of SH2 domains. , 2000, Current pharmaceutical design.

[25]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[26]  Jiayuh Lin,et al.  Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells , 2001, Oncogene.

[27]  W C Shakespeare,et al.  SH2 domain inhibition: a problem solved? , 2001, Current opinion in chemical biology.

[28]  Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. , 2001, Current medicinal chemistry.

[29]  A. Breeze,et al.  NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex. , 2001, Acta crystallographica. Section D, Biological crystallography.

[30]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[31]  J. Bromberg.  Stat proteins and oncogenesis. , 2002, The Journal of clinical investigation.

[32]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[34]  Markus H. Heim,et al.  Characterization of Phosphopeptide Motifs Specific for the Src Homology 2 Domains of Signal Transducer and Activator of Transcription 1 (STAT1) and STAT3* , 2003, The Journal of Biological Chemistry.

[35]  S. Hubbard,et al.  Structural Basis for Dimerization of the Grb10 Src Homology 2 Domain , 2003, The Journal of Biological Chemistry.

[36]  P. Andrews.  20 – THE ROLE OF FUNCTIONAL GROUPS IN DRUG–RECEPTOR INTERACTIONS , 2003 .

[37]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. McMurray,et al.  Identification of a high-affinity phosphopeptide inhibitor of Stat3. , 2003, Bioorganic & medicinal chemistry letters.

[39]  R. Daly,et al.  Solution structure of the human Grb7-SH2 domain/erbB2 peptide complex and structural basis for Grb7 binding to ErbB2 , 2003, Journal of biomolecular NMR.

[40]  R. Cook,et al.  Structural Requirements for Signal Transducer and Activator of Transcription 3 Binding to Phosphotyrosine Ligands Containing the YXXQ Motif* , 2004, Journal of Biological Chemistry.

[41]  J. Turkson,et al.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. , 2004, Molecular cancer therapeutics.

[42]  C. Müller,et al.  Structure of an activated Dictyostelium STAT in its DNA-unbound form. , 2004, Molecular cell.

[43]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[44]  J. Grandis,et al.  In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy , 2005, Oncogene.

[45]  L. Ellis,et al.  HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas , 2005, Oncogene.

[46]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Darnell,et al.  Structural bases of unphosphorylated STAT1 association and receptor binding. , 2005, Molecular cell.

[48]  S. Becker,et al.  Structure of the Unphosphorylated STAT5a Dimer* , 2005, Journal of Biological Chemistry.

[49]  Arlin G. Cameron,et al.  Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. , 2005, Journal of medicinal chemistry.

[50]  Huang Shao,et al.  Unique Structural Determinants for Stat3 Recruitment and Activation by the Granulocyte Colony-Stimulating Factor Receptor at Phosphotyrosine Ligands 704 and 7441 , 2006, The Journal of Immunology.

[51]  J. McMurray,et al.  Solid-phase synthesis of Stat3 inhibitors incorporating O-carbamoylserine and O-carbamoylthreonine as glutamine mimics. , 2007, Bioorganic & medicinal chemistry letters.

[52]  William P. Katt,et al.  Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. , 2007, Bioorganic & medicinal chemistry letters.

[53]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.